Introduction {#s1}
============

Smoking is the major cause of preventable mortality worldwide, accounting for cancer and cardiovascular disease [@pone.0074904-US1]. Faced with the facts, almost half of all smokers attempt to quit smoking each year, but with only 3% success rate [@pone.0074904-Shiffman1], [@pone.0074904-Hughes1]. Current guidelines for smoking cessation recommend use of effective medications for tobacco dependence in all smokers, except when medically contraindicated or with specific populations for which there is insufficient evidence of effectiveness (e.g. pregnant women, smokeless tobacco users, light smokers, and adolescents)[@pone.0074904-Clinical1]. In addition, use of smoking cessation medication is used as one of the indicators to evaluate the effectiveness of tobacco cessation interventions from the public health perspectives [@pone.0074904-International1].

Use of smoking cessation medication was studied in western countries, including US [@pone.0074904-Shiffman1], UK [@pone.0074904-Kotz1], Switzerland [@pone.0074904-Etter1], and so on. Those studies showed that many smokers attempt to quit unassisted ("cold turkey"), or opt for treatment with unknown efficacies [@pone.0074904-Shiffman2]. Such underuse of efficacious pharmacological treatment for smoking cessation was suggested to at least partly explain the discrepancy between quit intention and success [@pone.0074904-Shiffman2].

Treatment utilization may differ by different cultural and health system factors [@pone.0074904-Shiffman3]. However, to our knowledge, there has been no study which investigated the prevalence of smoking cessation medication use in Korean smokers trying to quit. In Korea, nicotine replacement therapy (NRT) has been available over-the-counter since 1995. As it does not require prescription by a physician, it has become widely used in government-led, public health center-based smoking cessation services throughout Korea [@pone.0074904-Oh1], as well as in company and university health promotion programs. Bupropion SR (Wellbutrin, sustained-release) and varenicline (Champix) have been available since 2002 and 2007 by prescription, respectively, but are still not reimbursed.

In this study which used a series of nationwide cross-sectional surveys in Korea performed from 2005 to 2011, we examined the prevalence of smoking cessation medication use and factors associated with it. This would reveal how the public health center-based government smoking cessation programs and introduction of varenicline may have influenced the use of smoking cessation medication in Korea. It will also contribute to understanding the use of smoking cessation medication in Asia.

Methods {#s2}
=======

Data Source and Participants {#s2a}
----------------------------

We analyzed data from the third to fifth waves of Korean National Health and Nutrition Examination Survey (KNHANES), which were conducted in 2005 (third), 2007--2009 (fourth), and 2010--2011 (fifth). The KNHANES is a nationally representative cross-sectional survey on the health and nutritional status of non-institutionalized Korean civilians, periodically conducted by Korean Center for Disease Control and Prevention (KCDC). Sampling units were by households from which data was collected through a stratified, multistage, probability-sampling design based on sex, age, and geographical area using household registries.

The participants for each KNHANES survey were informed that they had been randomly selected as a sample household, and voluntarily participated in the survey. A written informed consent was obtained. Average overall participation rate was around 80% during the study period. Each of the population was assigned a weighted value on the basis of geographical and demographic characteristics to allow estimates to be calculated for the entirety of the Korean population. As this study involved open data without any identifier, ethical review was not needed according to the policy of Seoul National University Hospital institutional review boards.

Measures {#s2b}
--------

The questionnaires related to smoking were self-reported. All respondents were asked about their current smoking status (by WHO definition) [@pone.0074904-World1], and their daily cigarette consumption amount. Current smokers were subsequently asked whether they had made a serious quit attempt during the past 12 months ("During the past 12 months, have you made any serious attempt to stop smoking" in 2005; "During the past 12 months, have you made any attempt to stop smoking lasting 24 hours or more" in 2007).

Smokers were also asked "Have you used any of the following methods to help you quit smoking?" The smoking cessation methods that respondents were queried about were: (1) NRT, including patch, gum, etc (over-the-counter or prescription was not discriminated); (2) prescribed medications (bupropion SR or varenicline was not discriminated); (3) smoking cessation herb, called "geumyeoncho" in Korea; (4) and others, which included quit line, smoking cessation acupuncture, and smoking education and counseling. Respondents were allowed to choose from more than one method, if they used more than one method. Smokers in the 4^th^ and 5^th^ waves were also asked whether they had participated in any education program about smoking prevention or cessation in the previous year.

Data on sociodemographic characteristics were also collected and included age, sex, education level, working status, household income, and perceived health status (as 1, very good to 5, very poor).

Statistical Analysis {#s2c}
--------------------

Primary analysis was limited to current smokers who reported having attempted to quit smoking during the past 12 months. Prevalence of each smoking cessation method use was calculated for each year, and its secular trend was tested by multivariate logistic regression. Use of multiple methods was not considered in the analyses, and each outcome was separately analyzed.

Multivariate logistic regression analyses were used to identify the factors associated with smoking cessation medication use. Age, sex, education level (categorized by high school and above, and less than high school), working status (employed, self-employed vs. unemployed, retired, student, housewife), income status (categorized by upper half, and lower half), and subjective health status (categorized as very good and good, fair, bad and very bad), daily cigarette consumption (categorized as \<10, 10 to 19, and ≥20 cigarettes per day), and survey year was included as independent variables. For subsamples of 4^th^ and 5^th^ year, we also included whether they had participated in any education program about smoking prevention or cessation in the previous year.

Weighted values of each subject were used to account for the complex sampling design, according to the KNHANES analytic guide published by KCDC. Statistical analyses were carried out using STATA software (version 12.0; STATA corp., Houston, TX). P-value \<0.05 (two sided) was regarded statistically significant.

Results {#s3}
=======

Study Participants {#s3a}
------------------

A total of 37,689 adults aged 19 years or more participated in the health behavior survey of KNHANES during the defined study period. Among them, 8382 (26.4%, weighted) were current smokers. Of them, 4,788 (57.7%, weighted) who reported having had any serious quit attempt in the previous year were included in primary analyses. There was no significant trend in the current smoking rate (P for trend = 0.139), but there was a slightly decreasing trend of quit attempts (P for trend = 0.002) **(** [**Figure 1**](#pone-0074904-g001){ref-type="fig"} **)**.

![Prevalence of current smoking rate and quit attempt among current smokers.](pone.0074904.g001){#pone-0074904-g001}

Mean age (standard error) of the participants was 40.2 (0.3), and most were male (87.9%). Most had at least high school education (79.1%), and were working (77.7%). Average daily cigarette consumption was 15.5 **(** [**Table 1**](#pone-0074904-t001){ref-type="table"} **)**.

10.1371/journal.pone.0074904.t001

###### Characteristics of study subjects (N = 4,788).

![](pone.0074904.t001){#pone-0074904-t001-1}

                                        Total sample (N = 4,788)   Subsample (N = 3,570)         
  ------------------------------------ -------------------------- ----------------------- ------ ------------
  Age, mean (SE)                                                        40.2 (0.3)                40.5 (0.3)
  Sex                                                                                            
  Male                                            4104                     87.9            3024      87.4
  Female                                          684                      12.1            546       12.6
  Education                                                                                      
  Less than high school (\<12 years)              1263                     20.9            999       21.7
  High school and above (≥12 years)               3511                     79.1            2557      78.3
  Employment status                                                                              
  Working                                         3634                     77.7            861       77.9
  Not working                                     1137                     22.3            2692      22.1
  Income                                                                                         
  Lower half                                      2505                     50.8            1817      49.6
  Upper half                                      2213                     49.2            1701      50.4
  Self-reported health status                                                                    
  Very good, good                                 1825                     37.6            1300      36.0
  Fair                                            2025                     45.2            1549      46.5
  Poor, very poor                                 929                      17.2            712       17.5
  Daily cigarette amount                                                                         
  0--9                                            1174                     23.3            876       23.3
  10--19                                          1885                     40.9            1419      41.0
  ≥20                                             1727                     35.8            1274      35.7
  Round                                                                                          
  III (2005)                                      1218                     18.5                  
  IV (2007--2009)                                 2137                     49.5            2137      60.8
  V (2010--2011)                                  1433                     32.0            1433      39.2

N: number.

Among smokers who made quit attempt during the previous year, 15.7% had used smoking cessation medications, 15.3% had used NRT, and 0.7% had used prescription medication. There was a significant increasing trend for NRT use (P\<0.001) during the study period, but use of prescription medication did not show any increase over time (P = 0.654) **(** [**Figure 2**](#pone-0074904-g002){ref-type="fig"} **)**. Use of smoking cessation herb was reported in 8.5% of those who made any attempt to quit, and remained stable throughout the period (P = 0.844).

![Prevalence of smoking cessation medication use during 2005--2011.](pone.0074904.g002){#pone-0074904-g002}

[Table 2](#pone-0074904-t002){ref-type="table"} shows the odds ratio (OR) and 95% confidence interval (CI) of factors associated with the use of smoking cessation medication in current smokers who had made any quit attempt during the previous year. The use of pharmacologic medications was significantly higher in smokers who smoked 10--19 cigarettes per day (adjusted odds ratio \[aOR\] 1.88, 95% confidence interval \[CI\] 1.38--2.54) and ≥20 cigarettes per day (aOR 2.69, 95% CI 1.96--3.69, respectively) than smokers who smoked \<10 cigarettes per day. Higher income was associated with higher use (aOR 1.22, 95% CI 1.01--1.48). There was an increasing trend by survey year (aOR 1.15, 95% CI 1.09--1.20). In subgroup analysis, education on smoking prevention and cessation was associated with smoking cessation medications use (OR 2.08, 95% CI 1.58--2.75). There were no associations in age, sex, household income, working status, and perceived health status with smoking cessation medication use.

10.1371/journal.pone.0074904.t002

###### Factors associated with smoking cessation medication use.

![](pone.0074904.t002){#pone-0074904-t002-2}

                                                                      Total sample (KNHANES III--V)   Subsample (KNHANES IV--V)                                                 
  ------------------------------------------------------------------ ------------------------------- --------------------------- ------------------- ------ ------------------- -------------------
  Year (per year)                                                                                                                 1.15 (1.09--1.20)                              1.17 (1.08--1.28)
  Age (per year)                                                                                                                  1.00 (0.99--1.01)                              1.00 (0.99--1.01)
  Sex                                                                                                                                                                           
  male                                                                            16.1                                                                17.2                      
  female                                                                          12.6                    0.75 (0.56--1.01)       1.03 (0.74--1.43)   13.1   0.72 (0.52--1.00)   1.05 (0.72--1.51)
  Education                                                                                                                                                                     
  Less than high school                                                           16.7                                                                 17                       
  High school and above                                                           15.4                    0.91 (0.72--1.15)       0.98 (0.73--1.31)   16.6   0.97 (0.74--1.26)   1.01 (0.72--1.40)
  Working                                                                                                                                                                       
  Not working                                                                     14.5                                                                16.3                      
  Working                                                                          16                     1.12 (0.89--1.42)       0.91 (0.71--1.18)   16.8   1.03 (0.80--1.35)   0.81 (0.61--1.08)
  Income status                                                                                                                                                                 
  Lower half                                                                      14.5                                                                15.7                      
  Upper half                                                                      16.6                    1.18 (0.99--1.42)       1.22 (1.01--1.48)   17.6   1.15 (0.94--1.41)   1.17 (0.94--1.46)
  Health status                                                                                                                                                                 
  Very good∼good                                                                  14.2                                                                15.6                      
  Fair                                                                            16.4                    1.18 (0.96--1.46)       1.08 (0.87--1.33)   17.3   1.13 (0.90--1.42)   1.06 (0.84--1.35)
  Very bad ∼bad                                                                   17.0                    1.24 (0.95--1.61)       1.14 (0.85--1.53)   17.3   1.13 (0.84--1.53)   1.07 (0.77--1.48)
  Smoking amount                                                                                                                                                                
  \<10 per/day                                                                     9.0                                                                9.7                       
  10--19 cigarettes/day                                                           15.3                    1.82 (1.36--2.44)       1.88 (1.38--2.54)   16.6   1.85 (1.34--2.56)   1.88 (1.34--2.65)
  ≥20 cigarettes/day                                                              20.5                    2.60 (1.94--3.48)       2.69 (1.96--3.69)   21.5   2.55 (1.84--3.54)   2.71 (1.89--3.88)
  Education about smoking prevention or cessation in previous year                                                                                                              
  No                                                                               NA                                                                 15.0                      
  Yes                                                                              NA                                                    NA           26.6   2.05 (1.57--2.68)   2.08 (1.58--2.75)

OR: odds ratio; CI: confidence interval.

All variables in the univariate analyses were included in multivariate model.

Discussion {#s4}
==========

To our knowledge, this is the first report about the prevalence and factors of smoking cessation medication use in a non-western country. Strengths include use of nationally representative data, and investigation of secular trends.

Overall, only 15.7% of smokers who had made any quit attempt during the past 12 months reported having used smoking cessation medication, and most of them used NRT. While studies persistently reported underuse of smoking cessation medication in quit attempts, figures in our study is even lower than those reported in previous studies: The reported prevalence of smoking cessation medication was 48.4% in UK (as of 2007) [@pone.0074904-Kotz1], 32.2% in US (as of 2003) [@pone.0074904-Shiffman1], and 24% in Switzerland (as of 2008--2009) [@pone.0074904-Etter1].

Smokers' attitudes toward smoking cessation medication largely determine the decision to use it. Skepticism about the effectiveness and concerns about the safety of smoking cessation medication was reported as a reason for underuse of smoking cessation medication [@pone.0074904-Shiffman2], [@pone.0074904-Hammond1]. Previous studies from Switzerland and US showed that only 1 or 2 of 6 participants agreed with the effectiveness of NRT for smoking cessation [@pone.0074904-Etter1], [@pone.0074904-Shiffman2], and many smokers underestimated the effectiveness of smoking cessation medication [@pone.0074904-Hammond1]. In addition, two-thirds of all US respondents harbored concerns about the safety of NRT, believing that "NRT was as harmful as cigarettes" [@pone.0074904-Shiffman2] and "nicotine can cause a heart attack or cancer" [@pone.0074904-Bansal1]. Swiss smokers also had concerns that NRT may maintain dependence by developing a new dependence [@pone.0074904-Etter1]. The term 'nicotine' is often used as a code word for the entire tobacco problem [@pone.0074904-Shiffman4], creating association of nicotine and harms of smoking. Long and detailed warning message from FDA for the NRT, compared to short warning message of cigarette packaging, may also have contributed to smokers' reluctance to use the products [@pone.0074904-Etter1], [@pone.0074904-Shiffman4]. Although previous data mainly addressed specifically misperceptions regarding NRT, similar misperceptions may also be attached to other medications and treatments [@pone.0074904-Shiffman2]. While few data are available regarding smokers' perception of bupropion SR and varenicline, publicity on the recent debate regarding potential risk of suicide [@pone.0074904-Moore1], and cardiovascular events [@pone.0074904-Prochaska1], [@pone.0074904-Singh1] may discourage smokers not to seek assistance in their attempt to quit smoking.

Another important factor of low use may include simple ignorance about the existence of smoking cessation medication [@pone.0074904-Hammond1]. In a survey on Swiss smokers regarding NRT, one fifth of the smokers answered that they neither know nor used the NRT [@pone.0074904-Etter1]. In a US study where almost all study respondents reported they have heard of nicotine patch and gum, only small proportions of them had heard about bupropion SR (63%), nicotine inhaler (41%), and nicotine spray (9%) [@pone.0074904-Bansal1]. Promoting the availability of evidence-based cessation methods may be suggested to improve the usage of efficacious cessation aids [@pone.0074904-Willemsen1].

Cultural norms affect treatment-seeking behaviors related to smoking cessation [@pone.0074904-Shiffman3], and may partly account for lower use in Korea. US studies showed that ethnicity could be a factor that can influence the utilization of treatment [@pone.0074904-Shiffman3], [@pone.0074904-Fu1], and non-white respondents were more likely than white respondents to harbor concerns about safety and efficacy of smoking cessation medication [@pone.0074904-Shiffman2]. It is also recognized that Asian Americans with addictive disorders face several cultural and practical barriers to treatment and the result has been an underutilization of addiction and mental health treatment. For example, shame in asking for help for an addictive disorder is perceived as one of the most recognized cultural barrier in this population [@pone.0074904-Fong1]. There are some preliminary evidence for the effectiveness of such culturally appropriate smoking cessation intervention [@pone.0074904-Chen1].

Our study shows that education on smoking prevention and cessation doubles the usage of smoking cessation medications. This may be because the education made smokers become aware of the availability of effective smoking cessation medication and to have better knowledge of and a more positive attitude toward medication. It is also possible that the NRT trial or referral to smoking cessation services were provided after the education session, which is currently a common practice in Korea [@pone.0074904-Korea1], [@pone.0074904-Webiste1]. As attitudes toward medication was more positive in ever-users than in never-users [@pone.0074904-Etter1], offering reluctant smokers an opportunity to try smoking cessation medication on a trial basis may be a way to improve knowledge about the safety and efficacy of these medications, and eventually increase smoking cessation [@pone.0074904-Bansal1].

The by far most commonly used medication was NRT. Furthermore, there was a significant trend in the overall use of NRT during the study period. This may be attributable to government-sponsored programs which were launched in 2004 under the direction of the Ministry of Health and Welfare. In this nationwide program, 253 public health centers located in all administrative districts provide free behavioral counseling and medication (mostly NRT) [@pone.0074904-Oh1]. Such increase in use of NRT was also experienced in UK (12% in 2000 to 28% in 2006), where a government strategy to systematically encourage treatment use was implemented by promoting both medications and specialist behavioral treatment [@pone.0074904-Kotz1]. Therefore, implementing government-led strategies can be considered effective to promote smoking cessation medication use.

In contrast, usage of prescription medication was very low and flat throughout the study period, even with the advent of an effective smoking cessation drug, i.e. varenicline. This is in contrast with the UK situation, where the use of varenicline increased from 0% in 2006 to 4.3% in 2008 resulting in decrease in the use of OTC NRT during the same period [@pone.0074904-Kotz1]. Such difference may be due to the difference in reimbursement policy. While physician's prescription for smoking cessation are reimbursed in the NHS-based UK primary care system [@pone.0074904-Kotz1], both prescription for smoking cessation and the drugs themselves are totally based on out-of-pocket cost in a fee-for-service based primary care system in Korea. A survey on Korean physicians with experience in smoking cessation services identified that high cost of medication for smoking cessation due to non-reimbursement (50.7%) and the absence of a medical fee on smoking cessation services (34.8%) were main barriers to active involvement in smoking cessation services [@pone.0074904-Kim1]. Therefore, change in the primary care reimbursement policy would be the necessary condition to maximize the use of prescription medication.

Heavy smokers were more likely to use smoking cessation medication. This is consistent with previous research, which also suggested that more heavily addicted smokers are more likely to use assistance in quitting [@pone.0074904-Shiffman1], [@pone.0074904-Moore1], [@pone.0074904-Hung1], [@pone.0074904-Cummings1]. Patients' own perception of high nicotine dependence, as well as physician's propensity to recommend medication to heavy smokers, may explain the result. Higher income was weakly, but significantly associated with higher smoking cessation medication use, suggesting disparity in access to the appropriate services. As NRT and counseling is provided for free in public health centers, it is likely that people with lower income do not have enough time for visiting public health centers. No association between the use of smoking cessation medication and other sociodemographic characteristics, such as age, sex, and educational status was observed.

Despite of the increase in smoking cessation medication use, we did not observe decline of overall smoking rate during the observation period, implying that most of the smokers' attempts were unsuccessful. There are some criticism about emphasis on smoking cessation medication and advocacy for unassisted cessation [@pone.0074904-Chapman1]. Critics concern about the increasing medicalization and commodification of cessation. They also argue that there is no population-based evidence of smoking rate decline with the use of smoking cessation medication [@pone.0074904-Wakefield1], [@pone.0074904-Cummings2], probably due to the lower effectiveness of the medication in the 'real world setting'. However, as shown in our study and others, more dependent smokers gravitate towards treatment [@pone.0074904-Shiffman1], [@pone.0074904-Moore1], [@pone.0074904-Hung1], [@pone.0074904-Cummings1], and such self-select would lead to a bias toward null [@pone.0074904-Shiffman5]. In addition, some observation studies also suggest improved quit rates among smokers who made self-initiated quit attempts and used medication [@pone.0074904-West1], [@pone.0074904-Miller1]. Even if the use of smoking cessation medication can increase the chance of success in individuals, limited utilization itself can make it difficult to detect any public health impact in the population level. Furthermore, staggering of smoking prevalence in Korea since 2007 is mainly due to weak tobacco control policies in Korea [@pone.0074904-World2].

In addition, the way smoking cessation medication is used is often not optimal. Under dose, and early discontinuation are common and reduce the effect of medication [@pone.0074904-Shiffman5], [@pone.0074904-Shiffman6]. Furthermore, only 1/5 of the smoking cessation medication users had adjuvant behavioral counseling [@pone.0074904-Shiffman1], [@pone.0074904-Pierce1]. Therefore, even faced with absence of decline in smoking cessation rate with increase in smoking cessation medication, we assert that the more appropriate approach should be encouraging the use of such medication with concomitant behavioral counseling to raise the effectiveness [@pone.0074904-Cummings1]. Reinforcing the smokers' motivation and optimizing treatment dosage strengths, formulation, and duration may result in a more pronounced effect on population trends in smoking behavior [@pone.0074904-Cummings1]. Depriving the smokers with nicotine dependence of the intervention with proven efficacy at least in randomized clinical trial settings will not solve the problem, and could be even viewed as unethical. No treatment can help a smoker who does not use it. Therefore, increasing utilization of effective treatment along with good behavioral support would be an appropriate approach to decrease smoking rates in the general population.

There are several limitations to be mentioned. First, this study relies on self-reported data, leading to recall bias and probably overestimation of smoking cessation medication use. Second, as this study is a secondary analysis of KNHANES, which the authors did not develop for the study purpose, the study lacked detailed measures about the perceived efficacy and safety concerns, and their experiences. A valid and reliable measure of such knowledge and attitudes would have enhanced the understanding of the reasons for underuse of smoking cessation medication [@pone.0074904-Etter1], [@pone.0074904-Shiffman2]. Third, secular trend analysis were performed within relatively short timeframe. However, our data was sufficient to see the effect of the government smoking cessation program, which was launched in 2004, and availability of varenicline, which has been released in the market from 2007.

Despite the above mentioned limitations, our study has important policy implications in public health perspectives for countries, in particular those with similar cultural background and health care system. Although over half of all smokers try to quit each year in Korea, less than one fifths of those who try to quit do so with the benefit of smoking cessation medication with proven efficacy. While the use of NRT has increased over years through government-sponsored smoking cessation programs, use of prescription drugs remained very low and flat probably due to lack of reimbursement. Education of smokers about effective smoking cessation methods and change in reimbursement policy are suggested to stimulate evidence-based smoking cessation practice.
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